{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-120797","form_type":"8-K","ticker":"MNKD","cik":"0000899460","company_name":"MANNKIND CORP","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.739272+00:00","generated_at":"2026-05-21T07:10:10.333833+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"MannKind Chief Medical Officer Burkhard Blank to depart; separation terms include $386K bonus","bullets":["Burkhard Blank stepped down as CMO and EVP R&D effective May 9, 2025, becoming non-executive employee.","Last day of employment is August 1, 2025; base salary continued for 13 weeks through Oct 31, 2025.","One-time special bonus of $386,000 payable in January 2026; COBRA premiums reimbursed until Oct 31.","Equity awards continue to vest while Blank remains employed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-120797","json":"https://secwatch.observer/filing/0001193125-25-120797.json","markdown":"https://secwatch.observer/filing/0001193125-25-120797.md","text":"https://secwatch.observer/filing/0001193125-25-120797.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000119312525120797/0001193125-25-120797-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000119312525120797/d915656d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T07:10:10.333833+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e212338552","claim":"Burkhard Blank changed role as Chief Medical Officer and Executive Vice President, Research & Development at MANNKIND CORP.","evidence_excerpt":"On May 9, 2025, MannKind Corporation (the “Company”) and Burkhard Blank, Chief Medical Officer and Executive Vice President, Research & Development, mutually agreed that Mr. Blank would step down from his role as an executive officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/899460/000119312525120797/0001193125-25-120797-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001104659-26-069317","ticker":null,"company_name":"Cornerstone Building Brands, Inc.","filed_at":"2026-06-02T14:32:08+00:00","headline":"Cornerstone Building Brands names Richard Dirkson as Corporate Controller; CAO departs","event_type":"leadership","sec_items":["5.02","5.07"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069317","json":"https://secwatch.observer/filing/0001104659-26-069317.json","markdown":"https://secwatch.observer/filing/0001104659-26-069317.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/883902/000110465926069317/0001104659-26-069317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/883902/000110465926069317/tm2616548d1_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 9, 2025, MannKind Corporation (the “Company”) and Burkhard Blank, Chief Medical Officer and Executive Vice President, Research & Development, mutually agreed that Mr. Blank would step down from his role as an executive officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/899460/000119312525120797/0001193125-25-120797-index.htm","comparable_excerpt":"On May 27, 2026, the Company appointed Richard Dirkson as Senior Vice President, Corporate Controller (principal accounting officer) of the Company, effective May 28, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/883902/000110465926069317/0001104659-26-069317-index.htm"}},{"accession":"0001317685-26-000018","ticker":"ALH","company_name":"Alliance Laundry Holdings Inc.","filed_at":"2026-06-02T13:16:32+00:00","headline":"COO International Jan Vleugels to retire Sept 30; Bob Calver named successor; new VP IR","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001317685-26-000018","json":"https://secwatch.observer/filing/0001317685-26-000018.json","markdown":"https://secwatch.observer/filing/0001317685-26-000018.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1317685/000131768526000018/0001317685-26-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1317685/000131768526000018/all-20260602.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 9, 2025, MannKind Corporation (the “Company”) and Burkhard Blank, Chief Medical Officer and Executive Vice President, Research & Development, mutually agreed that Mr. Blank would step down from his role as an executive officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/899460/000119312525120797/0001193125-25-120797-index.htm","comparable_excerpt":"Mr. Jan Vleugals, Chief Operating Officer International of Alliance Laundry Holdings Inc. (the “Company”), provided notice of his decision to retire effective as of September 30, 2026","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1317685/000131768526000018/0001317685-26-000018-index.htm"}},{"accession":"0001129928-26-000039","ticker":"ONCY","company_name":"ONCOLYTICS BIOTECH INC","filed_at":"2026-06-02T13:02:48+00:00","headline":"Oncolytics appoints Steve Glover to board, promotes John McAdory to COO","event_type":"leadership","sec_items":["5.02","8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001129928-26-000039","json":"https://secwatch.observer/filing/0001129928-26-000039.json","markdown":"https://secwatch.observer/filing/0001129928-26-000039.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000039/0001129928-26-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000039/oncy-20260602.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 9, 2025, MannKind Corporation (the “Company”) and Burkhard Blank, Chief Medical Officer and Executive Vice President, Research & Development, mutually agreed that Mr. Blank would step down from his role as an executive officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/899460/000119312525120797/0001193125-25-120797-index.htm","comparable_excerpt":"appointed John McAdory as Chief Operating Officer of the Company","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000039/0001129928-26-000039-index.htm"}},{"accession":"0001193125-26-252624","ticker":"ACHV","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2026-06-02T12:51:39+00:00","headline":"Achieve Life Sciences appoints Jeff Farrow and Dr. Reid Waldman to Board","event_type":"leadership","sec_items":["5.02"],"materiality_score":0.45,"calibrated_materiality_score":0.45,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-252624","json":"https://secwatch.observer/filing/0001193125-26-252624.json","markdown":"https://secwatch.observer/filing/0001193125-26-252624.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000119312526252624/0001193125-26-252624-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000119312526252624/achv-20260529.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 9, 2025, MannKind Corporation (the “Company”) and Burkhard Blank, Chief Medical Officer and Executive Vice President, Research & Development, mutually agreed that Mr. Blank would step down from his role as an executive officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/899460/000119312525120797/0001193125-25-120797-index.htm","comparable_excerpt":"the Board of Directors (the “Board”) of Achieve Life Sciences, Inc. (the “Company”) appointed Jeff Farrow and Reid Waldman, M.D. (together, the “Incoming Directors”), as directors, effective as of such date.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/949858/000119312526252624/0001193125-26-252624-index.htm"}},{"accession":"0001568651-26-000048","ticker":"OSCR","company_name":"Oscar Health, Inc.","filed_at":"2026-06-02T10:31:58+00:00","headline":"Oscar Health Co-Founder Schlosser transitions from CTO to Advisor to CEO","event_type":"leadership","sec_items":["5.02"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001568651-26-000048","json":"https://secwatch.observer/filing/0001568651-26-000048.json","markdown":"https://secwatch.observer/filing/0001568651-26-000048.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1568651/000156865126000048/0001568651-26-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1568651/000156865126000048/oscr-20260529.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 9, 2025, MannKind Corporation (the “Company”) and Burkhard Blank, Chief Medical Officer and Executive Vice President, Research & Development, mutually agreed that Mr. Blank would step down from his role as an executive officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/899460/000119312525120797/0001193125-25-120797-index.htm","comparable_excerpt":"Mr. Schlosser’s transition from President of Technology and Chief Technology Officer of the Company to Co-Founder & Advisor to the CEO.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1568651/000156865126000048/0001568651-26-000048-index.htm"}},{"accession":"0001104659-26-069164","ticker":"PAGP","company_name":"PLAINS GP HOLDINGS LP","filed_at":"2026-06-02T10:05:30+00:00","headline":"Plains GP Holdings announces CAO succession: Montgomery promoted, Herbold retiring","event_type":"leadership","sec_items":["5.02"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069164","json":"https://secwatch.observer/filing/0001104659-26-069164.json","markdown":"https://secwatch.observer/filing/0001104659-26-069164.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581990/000110465926069164/0001104659-26-069164-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581990/000110465926069164/tm2614304d4_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 9, 2025, MannKind Corporation (the “Company”) and Burkhard Blank, Chief Medical Officer and Executive Vice President, Research & Development, mutually agreed that Mr. Blank would step down from his role as an executive officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/899460/000119312525120797/0001193125-25-120797-index.htm","comparable_excerpt":"effective September 1, 2026, Russ Montgomery will be promoted to the position of Vice President, Accounting and Chief Accounting Officer of Plains All American GP LLC, the general partner of PAA, and PAA GP Holdings LLC, the general partner of PAGP.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1581990/000110465926069164/0001104659-26-069164-index.htm"}},{"accession":"0001104659-26-069156","ticker":"PAA","company_name":"PLAINS ALL AMERICAN PIPELINE LP","filed_at":"2026-06-02T10:03:41+00:00","headline":"Plains All American announces CAO retirement and Montgomery promotion effective Sep 1, 2026","event_type":"leadership","sec_items":["5.02"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069156","json":"https://secwatch.observer/filing/0001104659-26-069156.json","markdown":"https://secwatch.observer/filing/0001104659-26-069156.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070423/000110465926069156/0001104659-26-069156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070423/000110465926069156/tm2615397d2_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 9, 2025, MannKind Corporation (the “Company”) and Burkhard Blank, Chief Medical Officer and Executive Vice President, Research & Development, mutually agreed that Mr. Blank would step down from his role as an executive officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/899460/000119312525120797/0001193125-25-120797-index.htm","comparable_excerpt":"Chris Herbold, who previously served as Senior Vice President, Finance and Chief Accounting Officer of PAA and PAGP, is retiring from the company on August 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1070423/000110465926069156/0001104659-26-069156-index.htm"}},{"accession":"0001104659-26-069119","ticker":"AHCO","company_name":"AdaptHealth Corp.","filed_at":"2026-06-02T01:02:57+00:00","headline":"AdaptHealth amends 8-K to disclose COO Daniel McFadden's compensation: base salary raised to $550K, plus RSU grant","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069119","json":"https://secwatch.observer/filing/0001104659-26-069119.json","markdown":"https://secwatch.observer/filing/0001104659-26-069119.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725255/000110465926069119/0001104659-26-069119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725255/000110465926069119/tm2616604d1_8ka.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 9, 2025, MannKind Corporation (the “Company”) and Burkhard Blank, Chief Medical Officer and Executive Vice President, Research & Development, mutually agreed that Mr. Blank would step down from his role as an executive officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/899460/000119312525120797/0001193125-25-120797-index.htm","comparable_excerpt":"the appointment of Daniel McFadden as Chief Operating Officer of the Company, effective as of May 4, 2026","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1725255/000110465926069119/0001104659-26-069119-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}